Publications authored by Pollak Research staff members from 1978 to 2013. To browse the publications list by year of publication, please click on the year desired on the left-hand side vertical menu.
Alternatively, to browse the entire list of publications by a keyword, an author's name, or a phrase, please press both the "Ctrl" + "F" keys at the same time on your PC's keyboard and type the keyword(s) you wish to locate, followed by the "Enter" key. If you are a MAC user, please press both the "Command" + "F" keys at the same time to perform the same function (on some Apple keyboards, the "command" key also has an Apple logo). Please note that PDF versions of the older publications will be added in the future.
All publications from 1978 - 2013:
|
Hofmann J, Liao L, Pollak M, Wang Ye, Pfeiffer R, Baris D, Andreotti G, Lan Q, Landgren O, Rothman N, Purdue M. A prospective study of circulating adipokine levels and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 22: 472, 2013. |
|
|
Bao Y, Giovannucci E, Kraft P, Qian ZR, Wu C, Ogino S, Gaziano JM, Stampfer MJ, Ma J, Buring JE, Sesso H, Lee IM, Rifai N, Pollak MN, Jiao L, Lessin LS, Cochrane BB, Manson JE, Fuchs CS, Wolpin BM. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of 5 US cohorts. Cancer Epidemiol Biomarkers Prev. 2013 Mar 5. Epub ahead of print. |
|
|
Song Y, Chavarro JE, Cao Y, Qiu W, Mucci L, Sesso HD, Stampfer MJ, Giovannucci E, Pollak M, Liu S, Ma J. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr 143: 189-96, 2013. |
|
|
Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes Hl, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2013 Jan 11. Epub ahead of print. |
|
|
Lubik AA, Gunter JH, Hollier BG, Fazli L, Ettinger S, Stylianou N, Adomat H, Hendy SC, Gleave M, Pollak MN, Herington A, Nelson CC. Insulin-like growth factor-2 increases de novo steroidogenesis in prostate cancer cells. Endocr Relat Cancer. 2013 Jan 14. Epub ahead of print. |
|
|
Liao LM, Weinstein SJ, Pollak M, Li Z, Virtamo J, Albanes D, Chow WH, Purdue MP. Pre-diagnostic circulating adipokine concentrations and risk of renal cell carcinoma. Carcinogenesis 34: 109-12, 2013. |
|
|
Smiechowski BB, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 36: 124-9, 2013. |
|
|
Dallal CM, Brinton LA, Bauer DC, Buist DS, Cauley JA, Hue TF, Lacroix A, Tice JA, Chia VM, Falk R, Pfeiffer R, Pollak MN, Veenstra TD, Xu X, Lacey JV. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. Endocr Relat Cancer. 2012 Dec 5. |
|
|
Bao Y, Giovannucci EL, Kraft P, Stamfer MJ, Ogino S, Ma J, Buring JE, Sesson HD, Lee IM, Gaziano JM, Rifai N, Pollak MN, Cochrane BB, Kaklamani V, Lin JH, Manson JE, Fuchs CS, Wolpin BM. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst. 2012 Dec 14. |
|
|
Evdokimova V, Tognon CE, Benatar T, Yang W, Krutikov K, Pollak M, Sorensen PH, Seth A. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci Signal 5: ra92, 2012. |
|
|
Song Y, Chavarro JE, Cao Y, Qiu W, Mucci L, Sesso HD, Stampfer MJ, Giovannucci E, Pollak M, Liu S, Ma J. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr. 2012 Dec 19. |
|
|
Zakikhani M, Bazile M, Hashemi S, Javeshghani S, Avizonis D, Pierre JS, Pollak MN. Alterations in Cellular Energy Metabolism Associated with the Antiproliferative Effects of the ATM Inhibitor KU-55933 and with Metformin. PLoS One. 2012; 7 (11):e49513. Epub 2012 Nov 21. |
|
|
Eichholzer M, Platz EA, Bienstock JL, Monsegue D, Akereyeni F, Hollis BW, Horst R, Rifai N, Pollak MN, Barbir A, Agurs-Collins T, Rohrmann S. Racial variation in vitamin D cord blood concentration in white and black male neonates. Cancer Causes Control. 2012 Nov 9. |
|
|
Birmann BM, Neuhouser ML, Rosner B, Albanes D, Buring JE, Giles GG, Lan Q, Lee IM, Purdue MP, Rothman N, Severi G, Yuan JM, Anderson KC, Pollak M, Rifai N, Hartge P, Landgren O, Lessin L, Virtamo J, Wallace RB, Manson JE, Colditz GA. Pre-diagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 2012 Oct 16. |
|
|
Rice MS, Tworoger SS, Rosner BA, Pollak MN, Hankinson SE, Tamimi RM. Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses’ Health Studies. Breast Cancer Res Treat. 2012 Oct 21. |
|
|
Javeshghani S, Zakikhani M, Austin S, Bazile M, Blouin MJ, Topisirovic I, St-Pierre J, Pollak MN. Carbon source and myc expression influence the antiproliferative actions of metformin. Cancer Res. 2012 Oct 4. |
|
|
Liao LM, Weinstein SJ, Pollak M, Li Z, Virtamo J, Albanes D, Chow WH, Purdue MP. Pre-diagnostic circulating adipokine concentrations and risk of renal cell carcinoma. Carcinogenesis. 2012 Oct 6. |
|
|
Hofmann JN, Liao LM, Pollak MN, Wang Y, Pfeiffer RM, Baris D, Andreotti G, Lan Q, Landgren O, Rothman N, Purdue MP. A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood. 2012 Sep 24. |
|
|
Smiechowski BB, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care. 2012 Aug 24. |
|
|
Pollak M. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2: 778-90, 2012. |
|
|
Runchey SS, Pollak MN, Valsta LM, Coronado GD, Schwarz Y, Breymeyer KL, Wang C, Wang CY, Lampe JW, Neuhouser ML. Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study. Eur J Clin Nutr. 2012 Aug 15. |
|
|
Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H. Insulin-like growth factor receptor in breast cancer subtypes. Breast Cancer Res Treat 132: 131-42, 2012. |
|
|
Tognon CE, Martin MJ, Moradian A, Trigo G, Rotblat B, Cheng SW, Pollard M, Uy E, Chow C, Carboni JM, Gottardis MM, Pollak M, Morin GB, Sorensen PH. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. Oncogene 31: 1334-40, 2012. |
|
|
Gao Y, Katki H, Graubard B, Pollak M, Martin M, Tao Y, Schoen RE, Church T, Hayes RB, Greene MH, Berndt SI. Serum IGF1, IGF2, and IGFBP3 and risk of advanced colorectal adenoma. Int J Cancer 131: E105-13, 2012. |
|
|
Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG; Diabetes and Cancer Research Consortium (Dr. Pollak is a member). Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55: 1607-18, 2012. |
|
|
Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H; Diabetes and Cancer Research Consortium (Dr. Pollak is a member). Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55: 1619-32, 2012. |
|
|
*Hvid H, Fendt SM, Blouin MJ, Birman E, Voisin G, Svendsen AM, Frank R, Vander Heiden MG, Stephanopoulos G, Hansen BF, Pollak MN. Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. Endocr Relat Cancer. 2012 Jun 8. |
|
|
Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344: e3645, 2012. |
|
|
Jones LW, Antonelli J, Masko EM, Broadwater G, Lascola CD, Fels D, Dewhirst MW, Dyck JR, Nagendran J, Flores CT, Betof AS, Nelson ER, Pollak M, Dash RC, Young ME, Freedland SJ. Exercise modulation of the host – tumor interaction in an orthotopic model of murine prostate cancer. J Appl Physiol. 2012 May 17. |
|
|
Larsson O, Morita M, Topisirovic I, Alain T, Blouin MJ, Pollak M, Sonenberg N. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci USA. 2012 May 18. |
|
|
Jenkins CR, Schevchuk OO, Giambra V, Lam SH, Carboni JM, Gottardis MM, Holzenberger M, Pollak M, Humphries RK, Weng AP. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. Exp Hematol. 2012 May 18. |
|
|
Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH, Venkateswaran V. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis. 2012 May 22. |
|
|
Fung TT, Hu FB, Schulze M, Pollak M, Wu T, Fuchs CS, Giovannucci E. A dietary pattern that is associated with C-peptide and risk of colorectal cancer in women. Cancer Causes Control 23: 959-65, 2012. |
|
|
Gunter JH, Lubik AA, McKenzie I, Pollak M, Nelson CC. The interactions between insulin and androgens in progression to castrate-resistant prostate cancer. Adv Urol. 2012 Apr 3. |
|
|
Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker AV, Pollak MN. A phase 2 pharmacodynamic study of pre-operative figitumumab in patients with localized prostate cancer. Clin Cancer Res. 2012 May 2. |
|
|
Rajpathak SN, HE M, Sun Q, Kaplan RC, Muzumdar R, Rohan TE, Gunter MJ, Pollak M, Kim M, Pessin JE, Beasley J, Wylie-Rosett J, Hu FB, Strickler HD. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes. 2012 May 3. |
|
|
Kaplan RC, Buzkova P, Cappola AR, Strickler HD, McGinn AP, Mercer LD, Arnold AM, Pollak MN, Newman AB. Decline in circulating insulin-like growth factors and mortality in older adults: Cardiovascular Health Study All-Stars Study. J Clin Endocrinol Metab. 2012 Mar 22. |
|
|
Pollak M. Metformin and pancreatic cancer: a clue requiring investigation. Clin Cancer Res. 2012 Mar 31. Epub ahed of print. |
|
|
Pollak M, Gonzalez-Angulo AM. Metformin and hepatic carcinogenesis. Cancer Prev Res (Phila). 2012 Mar 31. |
|
|
Rice MS, Tamimi RM, Connolly JL, Collins LC, Shen D, Pollak MN, Rosner B, Hankinson SE, Tworoger SS. Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses’ Health Study II. Breast Cancer Res 14: R44, 2012. |
|
|
Zhang X, Giovannucci EL, Wu K, Smith-Warner SA, Fuchs CS, Pollak M, Willett WC, Ma J. Magnesium intake, plasma C-peptide, and colorectal cancer incidence in US women: a 28-year follow-up study. Br J Cancer. 2012 Mar 13. |
|
|
Faupel-Badger JM, Wang Y, Staff AC, Karumanchi SA, Stanczyk FZ, Pollak M, Hoover RN, Troisi R. Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. Cancer Causes Control. 2012 Mar 15. |
|
|
Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012 Feb 16. |
|
|
Ollberding NJ, Cheng I, Wilkens LR, Henderson BE, Pollak MN, Kolonel LN, Le Marchand L. Genetic variants, prediagnostic levels of insulin-like growth factors, insulin and glucose, and the risk of colorectal cancer: The Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev. 2012 Feb 21. |
|
|
Agurs-Collins T, Rohrmann S, Sutcliffe C, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, Rifai N, Pollak MN, Platz EA. Racial variation in umbilical cord blood sex steroid hormones and the insulin-like growth factor axis in African-American and white female neonates. Cancer Causes Control. 2012 Jan 18. |
|
|
*Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petruccelli LA, Birman E, Viollet B, Ferbeyre G, Pollak MN. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila). 2012 Jan 18. |
|
|
Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clinical Cancer Res 18: 40-50, 2012. |
|
|
Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci E, Stampfer MJ, Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 20: 2618-27, 2011. |
|
|
Wu K, Feskanich D, Fuchs CS, Chan AT, Willett WC, Hollis BW, Pollak MN, Giovannucci. Interactions between plasma levels of 25-hydroxyvitamin D, insulin-like growth factor (IGF)-1 and c-peptide with risk of colorectal cancer. PLoS One 6: e28520, 2011. |
|
|
Dool C, Mashhedi H, Zakikhani M, David S, Zhao Y, Birman E, Carboni JM, Gottardis M, Blouin MJ, Pollak MN. IGF-1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin responsive breast cancer. Endocr Relat Cancer. 2011 Sep 26. |
|
|
Faupel-Badger JM, Wang Y, Karumanchi SA, Stanczyk F, Pollak M, McElrath T, Hoover RN, Troisi R. Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. Cancer Causes Control 22: 1587-95, 2011. |
|
|
Segal Ed, Yasmeen A, Beauchamp MC, Rosenblatt J, Pollak M, Gotlieb WH. Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochem Biophys Res Commun. 2011 Oct 2. |
|
|
Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, WInquist E; for the Canadian Uro-Oncology Group. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 17: 5765-73, 2011. |
|
|
Zhang X, Giovannucci EL, Smith-Warner SA, Wu K, Fuchs CS, Pollak M, Willett WC, Ma J. A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women. Cancer Causes Control. 2011 Sep 11. |
|
|
Gao Y, Katki H, Graubard B, Pollak M, Martin M, Tao Y, Schoen RE, Church T, Hayes RB, Greene MH, Berndt SI. Serum IGF1, IGF2, and IGFBP3 and risk of advanced colorectal adenoma. Int J Cancer. 2011 Sep 19. |
|
|
Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, Herington A, Gleave ME, Pollak M, Nelson CC. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 71: 5754-64, 2011. |
|
|
Tognon CE, Martin MJ, Moradian A, Trigo G, Rotblat B, Cheng SW, Pollard M, Uy E, Chow C, Carboni JM, Gottardis MM, Pollak M, Morin GB, Sorensen PH. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. Oncogene. 2011 Aug 1. |
|
|
Medyouf H, Gusscott S, Wang H, Tseng JC, Wai C, Nemirovsky O, Trumpp A, Pflumio F, Carboni J, Gottardis M, Pollak M, Kung AL, Aster JC, Holzenberger M, Weng AP. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signalling. J Exp Med 208: 1809-22, 2011. |
|
|
Poole EM, Tworoger SS, Hankinson SE, Schernhammer ES, Pollak MN, Baer HJ. Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3. Am J Epidemiol 174: 642-51, 2011. |
|
|
Lipton A, Chapman JA, Demers L, Shepherd LE, Han L, Wilson CF, Pritchard KI, Leitzel KE, Ali SM, Pollak M. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA. 14. J Clin Oncol 29: 3605-10, 2011. |
|
|
Suissa A, Azoulay L, Dell’aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia. 2011 May 26. |
|
|
Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H. Insulin-like growth factor receptor in breast cancer subtypes. Breast Cancer Res Treat. 2011 May 15. |
|
|
Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH. Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. Gynecol Oncol 2011 Mar 7. |
|
|
Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS. Vitamin D status in patients with stage IV colorectal cancer: Findings from intergroup trial N9741. J Clin Oncol 29: 1599-606, 2011. |
|
|
Mireuta M, Hancock MA, Pollak M. Binding between insulin-like growth factor 1 and insulin-like growth factor binding protein 3 is not influenced by glucose or 2-deoxy-D-glucose. J Biol Chem 2011 Mar 9. |
|
|
Kaplan RC, Petersen AK, Chen MH, Teumer A, Glazer NL, Doring A, Lam CS, Friedrich N, Newman A, Muller M, Yang Q, Homuth G, Cappola A, Klopp N, Smith H, Ernst F, Psaty BM, Wichmann HE, Sawyer DB, Biffar R, Rotter JI, Gieger C, Sullivan LS, Volzke H, Rice K, Spyroglou A, Kroemer HK, Ida Chen YD, Manolopoulou J, Nauck M, Strickler HD, Goodarzi MO, Reincke M, Pollak MN, Bidlingmaier M, Vasan RS, Wallaschofski H. A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Hum Mol Genet 20: 1241-51, 2011. |
|
|
Douglas JB, Silverman DT, Weinstein SJ, Graubard BI, Pollak MN, Tao Y, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies. Cancer Epidemiol Biomarkers Prev 20:359-69, 2011. |
|
|
Azoulay L, Dell'Aniello S, Gagnon B, Pollak M, Suissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 20: 337-44, 2011. |
|
|
Tognon CE, Somasiri AM, Evdokimova VE, Trigo G, Uy EE, Melnyk N, Carboni JM, Gottardis MM, Roskelley CD, Pollak M, Sorensen PH. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Cancer Res 71: 1060-70, 2011. |
|
|
Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, Sun P, Narod SA; the Hereditary Breast Cancer Clinical Study Group. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 117: 1812-8, 2011. |
|
|
Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN. Pre-treatment levels of circulating free IGF-I identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 104: 68-74, 2011. |
|
|
Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 30: 1174-82, 2011. |
|
|
Takahara K, Tearle H, Ghaffari M, Gleave ME, Pollak M, Cox ME. Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression. Prostate 71: 525-37, 2011. |
|
|
Nimptsch K, Platz EA, Pollak MN, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. Int J Cancer 128: 660-7, 2011. |
|
|
Pritchard KI, Shepherd LE, Chapman JW, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O’Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol 29: 2011. |
|
|
Mashhedi H, Blouin MJ, Zakikhani M, David S, Zhao Y, Bazile M, Birman E, Algire C, Aliaga A, Bedell BJ, Pollak M. Metformin abolishes increased tumor (18)F-2-Fluoro-2-Deoxy-D-Glucose uptake associated with a high-energy diet. Cell Cycle 10: 2770-8, 2011. |
|
|
Potratz JC, Saunders DN, Wai DH, Ng TL, McKinney SE, Carboni JM, Gottardis MM, Triche TJ, Jurgens H, Pollak MN, Aparicio SA, Sorensen PH. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res 70: 8770-81, 2010. |
|
|
Grimaldi-Bensouda L, Marty M, Pollak M, Cameron D, Riddle M, Charbonnel B, Barnett AH, Boffetta P, Boivin JF, Evans M, Rossignol M, Benichou J, Abenhaim L; ISICA group. The international study of insulin and cancer. Lancet 376: 769-70, 2010. |
|
|
Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila Pa) 3: 1060-5, 2010. |
|
|
Thomas JA 2nd, Antonelli JA, Lloyd JC, Masko EM, Poulton SH, Phillips TE, Pollak M, Freedland SJ. Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. Prostate Cancer Prostatic Dis 13: 350-5, 2010. |
|
|
Major JM, Stolzenberg-Solomon RZ, Pollak MN, Snyder K, Virtamo J, Albanes D. Insulin-like growth factors and liver cancer risk in male smokers. Br J Cancer 103: 1089-32, 2010. |
|
|
Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia 53: 2086-8, 2010. |
|
|
Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F, Sonenberg N. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA 107: 14134-9, 2010. |
|
|
Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 19: 2298-306, 2010. |
|
|
Canzian F, Cox DG, Setiawan VW, Stram DO, Ziegler RG, Dossus L, Beckmann L, Blanche H, Barricarte A, Berg CD, Bingham S, Buring J, Buys SS, Calle EE, Chanock SJ, Clavel-Chapelon F, Delancey JO, Diver WR, Dorronsoro M, Haiman CA, Hallmans G, Hankinson SE, Hunter DJ, Husing A, Isaacs C, Khaw KT, Kolonel LN, Kraft P, Le Marchand L, Lund E, Overvad K, Panico S, Peeters PH, Pollak M, Thun MJ, Tjonneland A, Trichopoulous D, Tumino R, Yeager M, Hoover RN, Riboli E, Thomas G, Henderson BE, Kaaks R, Feigelson HS. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI Breast and Prostate Cancer Cohort Consortium. Hum Mol Genet 19: 3873-84, 2010. |
|
|
Hou M, Venier N, Sugar L, Musquera M, Pollak M, Kiss A, Fleshner N, Klotz L, Venkateswaran V. Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. BiochemBiophys Res Commun 397: 537-42, 2010. |
|
|
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin 60: 207-21, 2010. |
|
|
Inoue T, Zakikhani, David S, Algire C, Blouin MJ, Pollak M. Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man. Prostate 70: 1628-35, 2010. |
|
|
Major JM, Pollak MN, Snyder K, Virtamo J, Albanes D. Insulin-like growth factors and risk of kidney cancer in men. Br J Cancer 103: 132-5, 2010. |
|
|
Pollak M. Beyond steroid hormones: the new cancer endocrinology. Lancet Oncol 11: 501-2, 2010 |
|
|
Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolone LN, Tjonneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ, Ma J; {dagger}On behalf of the NCI Breast &Prostate Cancer Cohort Consortium. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Human Mol Genet 19: 3089-101, 2010. |
|
|
Mireuta M, Darnel A, Pollak M. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors 28: 243-55, 2010. |
|
|
Okereke OI, Kurth T, Pollak MN, Gaziano JM, Grodstein F. Fasting plasma insulin, c-peptide and cognitive change in older men without diabetes: results from the Physicians’ Health Study II. Neuroepidemiology 34: 200-7, 2010. |
|
|
Pollak M, Russell-Jones D. Insulin analogues and cancer risk: cause for concern or cause célèbre? Int J Clin Pract 64: 628-36, 2010. |
|
|
Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17: 351-60, 2010. |
|
|
Blouin MJ, Zhao Y, Zakikhani M, Algire C, Piura E, Pollak M. Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. Cancer Lett 298: 246-253, 2010. |
|
|
Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL, Pollak M. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res (Phila Pa) 3: 279-89, 2010. |
|
|
Gill JK, Wilkens LR, Pollak MN, Stanczyk FZ, Kolonel LN. Androgens, growth factors, and risk of prostate cancer: the multiethnic cohort. Prostate 70: 906-15, 2010. |
|
|
Flaig TW, Glode M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 70: 848-55, 2010. |
|
|
Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123: 271-9, 2010. |
|
|
Mucci LA, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ, Ma J. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 19: 484-91, 2010. |
|
|
Tsilidis KK, Brancati FL, Pollak MN, Rifai N, Clipp SL, Hoffman-Bolton J, Helzlsouer KJ, Platz EA. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 21: 1-10, 2010. |
|
|
Khalid S, Hwang D, Babichev Y, Kolli R, Altamentova S, Koren S, Goodwin PJ, Ennis M, Pollak M, Sonenberg N, Fantus IG. Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Res Treat 122: 647-59, 2010. |
|
|
Barbieri M, Paolisso G, Kimura M, Gardner JP, Boccardi V, Papa M, Hjelmborg JV, Christensen K, Brimacombe M, Nawrot TS, Staessen JA, Pollak MN, Aviv A. Higher circulating levels of igf-1 are associated with longer leukocyte telomere length in healthy subjects. Mech Ageing Dev 130: 771-6, 2009 |
|
|
Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor Figitumumab (CP-751,871) in combination with Paclitaxel and Carboplatin. J Thorac Oncol. 2009 Sep 10. |
|
|
Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug targets. 2009 Oct 1. |
|
|
Beauchamp MC, Knafo A, Yasmeen A, carboni JM, Gottardis MM, Pollak MN, Gotlieb WH. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecol Oncol. 2009 Aug 20. |
|
|
Pollak M. Macronutrient intake and cancer: how does dietary restriction influence tumor growth and why should we care? Cancer Prev Res(Phila Pa) 2:698-701, 2009. |
|
|
Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28: 3009-21, 2009. |
|
|
Su X, Colditz GA, Willett WC, Collins LC, Schnitt SJ, Connolly JL, Pollak MN, Rosner B, Tamimi RM. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. Int J Cancer. 2009 Jun 23. |
|
|
Dowling RJ, Pollak M, Sonenberg N. Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs 23: 77-91, 2009. |
|
|
Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Fokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, PIzzo SV, Freedland SJ. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (Phila Pa) 2: 557-65, 2009. |
|
|
Rohrmann S, Sutcliffe CG, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, Rifai N, Pollak MN, Agurs-Collins T, Platz EA. Racial variation in sex steroid hormones and the insulin-like growth factor axis in umbilical cord blood of male neonates. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1484-91. |
|
|
Pollak, M. Do cancer cells care if their host is hungry? Cell Metab 2009. |
|
|
Kaplan RC, Fitzpatrick AL, Pollak MN, Gardner JP, Jenny NS, McGinn AP, Kuller LH, Strickler HD, Kimura M, Psaty BM, Aviv A. Insulin-like growth factors and leukocyte telomere length: The cardiovascular health study. J Gerontol A Biol Sci Med Sci 2009 Apr 6. |
|
|
Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M. Insulin receptor expression by human prostate cancers. The Prostate 69: 33-40, 2009. |
|
|
Pollak, M. Aging, IGF-1, and diet. Aging Cell. 2009 Mar 5. |
|
|
Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 69: 2443-52, 2009. |
|
|
Pollak M. Energy metabolism, cancer risk, and cancer prevention. Recent Results Cancer Res 181: 51-4, 2009. |
|
|
Sinotte M, Diorio C, Berube S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 89: 634-40, 2009. |
|
|
Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27: 176-85, 2009. |
|
|
Okereke OI, Selkoe DJ, Pollak MN, Stampfer MJ, Hu FB, Hankinson SE, Grodstein F. A profile of impaired insulin degradation in relation to late-life cognitive decline: A preliminary investigation. Int J Geriatr Psychiatry 24: 177-82, 2009. |
|
|
Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68: 10238-46, 2008. |
|
|
Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22: 625-38, 2008. |
|
|
So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MCU, Nielsen TO, Gleave M, Pollak M. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 14: 6944-54, 2008. |
|
|
Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Cancer Rev 8: 915-28, 2008. |
|
|
Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10: R86, 2008. |
|
|
Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364-70, 2008. |
|
|
Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schröder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149: 461-71,W83-8, 2008. |
|
|
Stolzenberg-Solomon RZ, Weinstein S, Pollak M, Tao Y, Taylor PR, Virtamo J, Albanes D. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol 168: 1047-55, 2008. |
|
|
Fuchs CS, Goldberg RM, Sargen DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma insulin-like growth factors, insulin-like binding protein-3 and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res 14: 8263-9, 2008. |
|
|
Diorio C, Sinotte M, Brisson J, Berube S, Pollak M. Vitamin d pathway polymorphisms in relation to mammographic breast density. Cancer epidemiol Biomarkers Prev 17: 2505-8, 2008. |
|
|
Zakikhani M, Dowling RJO, Sonenberg N, Pollak MN. Effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 1: 369-75, 2008. |
|
|
Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen P, Gaziano JM, Pollak M, Stampfer M. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9: 1039-47, 2008. |
|
|
Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 8: 384-92, 2008. |
|
|
Page JH, Ma J, Pollak M, Manson JE, Hankinson SE. Plasma insulin-like growth factor 1 and binding-protein 3 and risk of myocardial infarction in women: a prospective study. Clin Chem 54: 1682-8, 2008. |
|
|
Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossu L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS. IGF-1, IGFBP-1, IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE. 3: e2578, 2008. |
|
|
Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate 68: 1477-86, 2008. |
|
|
Max JB, Limburg PJ, Ogunseitan A, Stolzenberg-Solomon RZ, Vierkant RA, Pollak M, Sellers TA, Virtamo J, Cerhan JR, Albanes D. IGF-I, IGFBP-3, and IGF-I/IGFBP-3 Ratio: No Association with Incident Colorectal Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiol Biomarkers Prev. 17: 1832-4, 2008. |
|
|
Kaplan RC, McGinn AP, Pollak MN, Kuller L, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM. High insulinlike growth factor binding protein 1 level predicts incident congestive heart failure in the elderly. Am Heart J. 155: 1006-12, 2008. |
|
|
Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 110: 246-50, 2008. |
|
|
Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S, Richardson P, Gualberto A. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol. 26: 3196-203, 2008. |
|
|
Diorio C, Brisson J, Berube S, Pollak M. Intact and total insulin-like growth factor-binding protein-3 levels in relation to breast cancer risk factors: a cross-sectional study. Breast Cancer Res. 10: R42, 2008. |
|
|
Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 15: 833-9, 2008. |
|
|
Van Oijen M, Okereke OI, Kang JH, Pollak MN, Hu FB, Hankinson SE, Grodstein F. Fasting insulin levels and cognitive decline in older women without diabetes. Neuroepidemiology. 30: 174-9, 2008. |
|
|
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, Einstein MH, Kaplan RC, Burk RD, Wylie-Rosett J, Pollak MN, Anderson G, Howard BV, Strickler HD. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarker Prev. 17: 921-9, 2008. |
|
|
Diorio C, Brisson J, Berube S, Pollak M. Genetic polymorphisms involved in insulin-like growth factor (IGF-I) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev. 17: 880-8, 2008. |
|
|
Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Roger M, Franco EL; Biomarkers of Cervical Cancer Risk (BCCR) Study Team (Michael Pollak is member). Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 122: 2820-6, 2008. |
|
|
Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E. Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control.19:703-710, 2008. |
|
|
Kaplan RC, McGinn AP, Pollak MN, Kuller L, Strickler HD, Rohan TE, Xue X, Kritchevsky SB, Newman AB, Psaty BM. Total insulin like growth factor 1 and insulin like growth factor binding protein levels, functional status, and mortality in older adults. J Am Geriatr Soc 56: 652-60, 2008. |
|
|
Okereke OI, Pollak MN, HU FB, Hankinson SE, Selkoe DJ, Grodstein F.Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. Psychoendocrinology.33:455-461, 2008. |
|
|
Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak M, Whittemore AS, Wu AH, Gallagher RP. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study. Cancer Epidemiol Biomarkers Prev. 17: 252-4, 2008. |
|
|
Rajpathak SN, McGinn AP, Strickler HD, Rohan TE, Pollak M, Cappola AR, Kuller L, Xue X, Newman AB, Strotmeyer ES, Psaty BM, Kaplan RC. Insulin-like growth factor axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res. 18:166-173, 2008. |
|
|
Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99: 1793-800, 2007. |
|
|
Singh RP, Deep G, Blouin M-J, Pollak MN, Agarwal R. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 28:2567-74, 2007. |
|
|
Schernhammer ES, Tworoger SS, Eliassen AH, MIssmer SA, Holly JM, Pollak MN, Hankinson SE. Body shape throughout life and correlations with IGFs and GH. Endocrine-Related Cancer 14:721-732, 2007. |
|
|
Raina K, Blouin M-J, Singh RP, Majeed N, Deep G, Varghese L, Glodé LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 67:11083-91, 2007. |
|
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-12, 2007. |
|
|
Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak M, Whittemore AS, Wu AH, Gallagher RP. Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16: 2164-5, 2007. |
|
|
Rich-Edwars JW, Ganmaa D, Pollak MN, Nakamoto EK, Kleinman K, Tserendolgor U, Willett WC, Frazier AL. Milk consumption and the prepubertal somatotropic axis. Nutr J 6: 28, 2007. |
|
|
Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak M, Fuchs CS. Circulating insulin-like growth factor and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer. 97: 98-104, 2007. |
|
|
Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, Manson JE, Pollak M, Ma J, Fuchs CS. Prediagnostic plasma C-Peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev. 16:2101-9, 2007. |
|
|
Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak M, Fuchs CS. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res. 67: 7923-8, 2007. |
|
|
Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ. Hypoxia-inducible factor-1 alpha gene polymorphisms, circulating insulin-like growth factor binding protein-3 levels and prostate cancer. Prostate. 67: 1354-91, 2007. |
|
|
Tworoger SS, Lee IM, Buring JE, Pollak MN, Hankinson SE. Insulin-like growth factors and ovarian risk: a nested case-control study in three cohorts. Cancer Epidemiol Biomarkers Prev. 16: 1691-5, 2007. |
|
|
Pollak MN. Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr. 86: 820S-2S, 2007. |
|
|
De Bono JS, Attard G, Adjei A,Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res. 13: 3611-6,2007. |
|
|
Levitt RJ, Zhao Y, Blouin M-J, Pollak M. The hedgehog pathway inhibitor cyclopamine increase levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer Lett. 255:300-6, 2007. |
|
|
Brisson J, Berube S, Diorio C, Sinotte M, Pollak M, Masse B. Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev. 16: 929-33, 2007. |
|
|
McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 109: 933-41, 2007. |
|
|
Lonn S, Inskip PD, Pollak MN, Weinstein SJ, Virtamo J, Albanes D. Glioma risk in relation to serum levels of insulin-like growth factors. Cancer Epidemiol Biomarkers Prev. 16: 844-6, 2007. |
|
|
Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Pollak MN, Franco EL. Insulin-like growth factor-I and risk of high-grade cervical intraepihtelial neolplasia. Cancer Epidemiol Biomarkers Prev. 16: 716-22, 2007. |
|
|
Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM. Association of total IGF-I, IGFBP-1 and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab. 92: 1319-25, 2007. |
|
|
Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, Freedman ML, Hankinson SE, Hunter DJ, Colditz GA. Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res. 9: R18, 2007. |
|
|
Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res. 174: 49-53, 2007. |
|
|
Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE. Circulating insulin and C-peptide levels and risk of breast cancer among predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev. 16: 161-4, 2007. |
|
|
Okereke O, Kang JH, Ma J, Hankinson SE, Pollak MN, Grodstein F. Plasma IGF-I levels and cognitive performance in older women. Neurobiol Aging.: 28: 135-42, 2007. |
|
|
Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene. 26: 1811-9, 2007. |
|
|
Tran CD, Diorio C, Berube S, Pollak M, Brisson J. Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. Am J Clin Nutr 2006 Dec; 84(6): 1518-26. |
|
|
Ahn J, Weinstein SJ, Snyder K, Pollak MN, Virtamo J, Albanes D. No association between serum insulin-like growth factor (IGF)-1, IGF-binding protein-3, and lung cancer. Cancer Epidemiol Biomarkers Prev 15: 2010-2, 2006. |
|
|
Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR. Obesity, diabetes, and risk of prostate cancer: Results from the prostate cancer prevention trial. Epidemiol Biomarkers Prev 15: 1977-83, 2006. |
|
|
Zakikhani M, Dowling R, Fantus GI, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research, 66: 10269-73, 2006. |
|
|
Tseng PH, Weng SC, Wang YC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol,1534-41, 2006. |
|
|
Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-1, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Related Cancer., 13: 583-92, 2006. |
|
|
Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2-3 year period. Cancer Epidemiol Biomarkers Prev. 15:972-8, 2006. |
|
|
Harris TG, Strickler HD, Yu H, Pollak MN, Monrad ES, Travin MI, Xue X, Rohan TE, Kaplan RC. Specimen processing time and measurement of total insulin-like growth factor-1 (IGF-1), free IGF-1, and IGF binding protein-3 (IGFBP-3). Growth Horm IGF Res. 16: 86-92, 2006. |
|
|
Wei EK, Ma J, Pollak MN, Rifai N, Fuchs C, Hankinson SE, Giovannucci E. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev., 15: 750-5, 2006. |
|
|
Gotlieb W, Bruchim I, Gu J, Shi Y, Camirand A, Blouin M-J, Zhao Y, Pollak MN. Insulin-like growth factor receptor 1 targeting in epithelial ovarian cancer. Gynecol Oncol., 100: 389-96, 2006. |
|
|
Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer., 118: 2105-9, 2006. |
|
|
Rollison DE, Newschaffer CJ, Tao Y, Pollak M, Helzlsouer KJ. Premenopausal levels of circulating insulin-like growth factor 1 and the risk of postmenopausal breast cancer. Int J Cancer., 118: 1279-84, 2006. |
|
|
Diorio C, Bérubé S, Byrne C, Mâssé B, Hébert-Croteau N, Yaffe M, Côté G, Pollak M, Brisson J. Influence of insulin-like growth factors on the strength of the relation of vitamin D and calcium intakes to mammographic breast density. Cancer Res. 66: 588-97, 2006. |
|
|
Diorio C, Pollak M, Byrne C, Mâssé B, Hébert-Croteau N, Yaffe M, Côté G, Bérubé S, Brisson J. Levels of C-peptide and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14: 2661-4, 2005. |
|
|
Levitt R, Georgescu M, Pollak M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem and Biophys Res Comm 336: 1056-61, 2005. |
|
|
Kucab JE, Lee C, Chen CH, Zhu J, Blake Gilks C, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn S. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 7: R796-R807, 2005. |
|
|
Pinheiro SP, Holmes MD, Pollak MN, Barieri R, Hankinson S. Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev 14: 2147-53, 2005. |
|
|
Bérubé S, Diorio C, Mâssé B, Hébert-Croteau N, Byrne C, Côté G, Pollak M, Yaffe M, Brisson J. Vitamin D and calcium intakes from food or supplements and mammographic breast density. Cancer Epidemiol Biomarkers Prev. 14: 1553-9, 2005. |
|
|
Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak M. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 24: 4736-40, 2005. |
|
|
Camirand A, Zakikhani M, Young F, Pollak MN. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibatory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Research 7: R570-9, 2005. |
|
|
Sutherland BW, Kucab J, Wu J, Lee C, Cheang M, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-92, 2005. |
|
|
Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes and Control 16: 255-62, 2005. |
|
|
Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson SK, Findlay BP, Fuchs CS. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Biomarkers Prev 14: 1402-10, 2005. |
|
|
Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Berube S, Morin C, Brisson J. Insulin-like growth factor-1, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev. 14: 1065-73, 2005. |
|
|
Nam RK, Trachtenberg J, Jewitt MA, Toi A, Evans A, Narod SA, Pollak M. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiology, Biomarkers Prev. 14: 1270-3, 2005. |
|
|
Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 14: 850-5 2005. |
|
|
Kristal AR, King IB, Albanes D, Pollak MN, Stanzyk FZ, Santella RM, Hoque A. Centralized blood processing for the selenium and vitamin E cancer prevention triaL: Effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. Cancer Epidemiology, Biomarkers & Prevention 14: 727-730, 2005. |
|
|
Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 3: 699-704, 2005. |
|
|
Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 23: 455-60, 2005. |
|
|
Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Solicited Review. Nature Rev Cancer 4: 505-18, 2004. |
|
|
Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 90: 1825-29, 2004. |
|
|
Stolzenberg-Solomon RZ, Limburg P, Pollak M, Taylor PR, Virtamo J, Albanes D. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol Biomarkers Prev 13: 438-44, 2004. |
|
|
Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA. A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiology Biomarkers Prev 13: 573-82, 2004. |
|
|
Ma J, Giovannucci EL, Pollak MN, Leavitt A, Tao Y, Gaziano J, Stampfer MJ. A prospective study of plasma c-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96: 546-53, 2004. |
|
|
Labrie F, Champagne P, Labrie C, Roy J, Laverdiere J, Provencher L, Potvin M, Drolet Y, Pollak M, Panasci L, L'Esperance B, Dufresne J, Latreille J, Robert J, Samson B, Jolivet J, Yelle L, Cusan L, Diamond P, Candas B. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer. J Clin Oncol 22: 864-71, 2004. |
|
|
Levitt RJ, Buckley J, Blouin M-J, Schaub B, Triche TJ, Pollak M. Growth inhibiton of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun 316: 421-8, 2004. |
|
|
Schairer C, Hill D, Fears T, Ziegler R, Hoover R, Pollak M. Serum concentrations of IGF-I, IGFBP-3, and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 108: 773-9, 2004. |
|
|
Lu Y, Zi X, Zhao Y,Pollak MN. Overexpression of ErbB2 receptor inhibits IGF-1-induced Shc-MAPK signaling pathway in breast cancer cells. Biochem Biophys Res Commun 313:709-15, 2004. |
|
|
Lu Y, Zi X, Pollak MN. Molecular mechanisms underlying IGF-1-induced attenuation of the growth inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108: 334-41, 2004. |
|
|
Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprinin D, Chu W, Ho M, Sweet J, Toi A, Pollak M, Narod SA. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev., 12: 1429-37,2003. |
|
|
Pollak M, Foulkes W. Challenges to cancer control by screening. Nature Reviews Cancer, 3: 297-303, 2003. |
|
|
Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, Willet WC. Nutritional predictors of insulin-like growth factor-I and their relationships to cancer in men. Cancer Epidemiology, Biomarkers & Prevention, 12: 84-89, 2003. |
|
|
Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiology, Biomarkers & Prevention, 12(5): 412-418, 2003. |
|
|
Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. International Journal of Cancer, 107(1): 60-64, 2003. |
|
|
Nomura AM, Stemmermann GN, Lee J,Pollak MN. Serum Insulin-like Growth Factor 1 and Subsequent Risk of Colorectal Cancer among Japanese-American Men. American Journal of Epidemiology, 158(5): 424-431, 2003. |
|
|
Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Research 63: 3991-4, 2003. |
|
|
Ismail AH,Pollak M, Behlouli H, Tanguay S, Bégin LR, Aprikian AG. Serum insulin-like growth factor (IGF) – 1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. British Journal of Urology International 92:699-702, 2003. |
|
|
VanHouten JN, Dann P, Stewart AF, Watson CJ, Karaplis AC,Pollak M, Wysolmerski JJ. Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. The Journal of Clinical Investigation 112: 1429-1436, 2003. |
|
|
Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O. Soy isoflavones in the treatment of prostate cancer. Nutri. Cancer 47: 111-7, 2003. |
|
|
Ismail AH, Pollak M, Behlouli H, Tanguay S, Bégin LR, Aprikian AG. Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. The Journal of Urology, 168: 2426-30, 2002. |
|
|
Camirand A, Lu YH, Pollak M. Co-targeting HER2/erbB2 and IGF-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Medical Science Monitor, 8: BR521-526, 2002. |
|
|
Levitt RJ, Pollak M. Insulin-like growth factor-I antagonizes the anti-proliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Research, 62: 7372-7376, 2002. |
|
|
Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, Khachik F, Banerjee M, Bertram JS, Wood DP Jr. Effects of lycopene supplementation in patients with localized prostate cancer. Experimental Biology and Medicine, 227: 881-885, 2002. |
|
|
Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M. Serum Insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: A case-control study nested in the beta-carotene and retinol efficacy trial cohort. Cancer Epidemiology Biomarkers & Prevention, 11: 1413-1418, 2002. |
|
|
Giovannucci E, Haiman CA, Platz EA, Hankinson SE, Pollak MN. Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. Cancer Epidemiology Biomarkers & Prevention, 11: 1509-1510, 2002. |
|
|
Deitel K, Dantzer D, Ferguson P, Pollak M, Beamer W, Andrulis I, Bell R. Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation. Journal of Surgical Oncology, 81: 75-79, 2002. |
|
|
Holmes MD, Pollak MN, Hankinson SE. Lifestyle correlates of plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 concentrations. Cancer Epidemiology, Biomarkers & Prevention, 11: 862-867, 2002. |
|
|
Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 concentrations. Cancer Epidemiology, Biomarkers & Prevention, 11: 852-861, 2002. |
|
|
Kucuk O, Sarkar FH, Sakr W, Khachik F, Djuric Z, Banerjee M, Pollak MN, Bertram JS, Wood DP. Lycopene in the treatment of prostate cancer. Pure and Applied Chemistry, 74: 1443-50, 2002. |
|
|
Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, Pollak MN, Hankinson SE. A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. International Journal of Cancer, 100: 332-6, 2002. |
|
|
Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clinical Cancer Research, 8: 670-8, 2002. |
|
|
Giovannucci E, Pollak M. Risk of cancer after growth-hormone treatment. [editorial] Lancet, 360: 268-9, 2002. |
|
|
Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. Journal of the National Cancer Institute, 94: 1099-1106, 2002. |
|
|
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). Journal of the National Cancer Institute, 93: 1852-1857, 2001. See also favourable editorial comment [.pdf] |
|
|
Ma J, Giovannucci E, Pollak M, Chan JM, Gaziano JM, Willett W, Stampfer MJ. Milk intake, circulating levels of insulin like growth factor-I and risk of colorectal cancer in men. Journal of the National Cancer Institute, 93: 1330-1336, 2001. |
|
|
Chan TW, Pollak M, Huynh H. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. Clinical Cancer Research, 7: 2545-2554, 2001. |
|
|
Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak M N, Khachik Y, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP Jr. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer, Epidemiology, Biomarkers & Prevention, 10: 861-8, 2001. |
|
|
Thorner M and writing committee (including Pollak M). Critical evaluation of the safety of recombinant human growth hormone administration: Statement from the growth hormone research society. Journal of Clinical Endocrinology & Metabolism, 86;5:1868-1870, 2001. |
|
|
Nickerson T, Chang F, Tran C, Lorimer D, Smeekens SP, Sawyers CI, Pollak M. In vivo of LAPC-9 and LNCaP cancer models to androgen independence is associated with increased expression of IGF-I and IGF-IR. Cancer Research, 61:6276-6280, 2001. |
|
|
He B, Deckelbaum RA, Miao D, Lipman ML, Pollak M, Goltzman D, Karaplis AC. Tissue-Specific targeting of the Pthrp gene: The generation of mice with floxed alleles. Endocrinology, 142;5:2070-7, 2001. |
|
|
Chokkalingam AP, Pollak M, Fillmore C, Gao Y, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW. Insulin-like growth factors and prostate cancer: a population-based cased-control study in China. Cancer Epidemiology, Biomarkers & Prevention, 10:421-7, 2001. |
|
|
Pollak M, Blouin M-J, Jian-Chun Z, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. British Journal of Cancer, 85: 428-430, 2001. |
|
|
Tolcher AW, Kennedy A, Padley RJ, Majeed N, Pollak M, Kantoff PW. Other novel agents: Rationale and current status as chemopreventive agents. Urology, 57:86-9, 2001. |
|
|
Chokkalingam AP, McGlynn KA, Gao Y, Pollak M, Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr, Hsing AW. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Research, 61: 4333-6, 2001. |
|
|
Pollak M. Insulin-like growth factors (IGFs) and prostate cancer. Epidemiologic Reviews, 23;1: 59-66, 2001. |
|
|
Trojan D, Collet J, Pollak M, Shapiro S, Jubelt B, Miller R, Agre J, Munsat TL, Hollander D, Tandan R, Robinson A, Finch L, Ducruet T, Cashman N. Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome. Journal of the Neurological Sciences, 182:107-115, 2001. |
|
|
Jernström H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M, and Narod SA. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for pre-menopausal breast cancer risk. Molecular Genetics and Metabolism, 72: 144-54, 2001. |
|
|
Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M. Novel promoter polymorphism in IGFBP3: Correlation with serum levels and interaction with known regulators. Journal of Clinical Endocrinology & Metabolism, 86: 1274-80, 2001. |
|
|
Jernström H, Wilkin F, Deal C, Chu W, Tao Y, Majeed N, Narod S, Hudson T,Pollak M. Genetic and non-genetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in healthy premenopausal women. Cancer Epidemiology, Biomarkers & Prevention, 10: 377-384, 2001. |
|
|
Nabholtz J, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, Von Euler M. Anastrazole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. J Clin Oncol 18: 3758-67, 2000. |
|
|
Pollak M. The question of a link between insulin-like growth factor physiology and neoplasia. Growth Hormone IGF Res. 10 Suppl B: 21-4, 2000. |
|
|
Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60: 5617-20, 2000. |
|
|
Byrne C, Colditz G, Willett W, Speizer F, Pollak M, Hankinson S. Plasma Insulin-like Growth Factor (IGF) I, IGF-binding Protein 3, and mammographic Density. Cancer Res 60: 3744-8, 2000. |
|
|
Wilkin F, Paquette J, Ledru E, Mamelin C, Pollak M, Deal C. H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. Eur J Biochem. 267: 4020-7, 2000. |
|
|
Platz EA, Pollak MN, Willett W, Giovannucci E. Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3. J Am Acad Dermatol. 42: 1003-7, 2000. |
|
|
Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36: 1224-8, 2000. |
|
|
Giovannucci E, Pollak M, Platz E, Willett W, Stampfer M, Majeed N, Colditz G, Speizer F, Hankinson S. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev. 9: 345-9, 2000. |
|
|
Foulkes WD, Chappuis PO, Wong N, Brunet J, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Bégin LR. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol. 3: 307-13, 2000. |
|
|
Miyake H, Pollak M, Gleave M. Castration-induced upregulation of IGFBP-5 potentiates IGF-I activity and accelerates progression to androgen-independence in prostate cancer models. Cancer Res. 60: 3058-64, 2000. |
|
|
Huynh H, Beamer W, Pollak M, Chan T. Modulation of transforming growth factor beta 1 gene expression in the mammary gland by insulin-like growth factor I and octreotide. Int J Oncol. 16: 277-81, 2000. |
|
|
Platz E, Pollak M, Rimm E, Majeed N, Tao Y, Willett W, Giovannucci E. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 8: 1107-10, 1999. |
|
|
Nickerson T, Pollak M. Bicalutamide (Casodex)-induced prostate regression involves increased gene expression of insulin-like growth factor binding proteins. Urology 54: 1120-5, 1999. |
|
|
Buhlmann C, Borchers T, Pollak M, and Spener F. Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein. Mol Cell Biochem 199: 41-8, 1999. |
|
|
Rozen F, Pollak M. Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol. 15: 589-94, 1999. |
|
|
Nickerson T, Miyake H, Gleave M, and Pollak M Castration-induced apoptosis of androgen-dependent Shinogi carcinoma is associated with increased expression of genes encoding IGF-binding proteins. Cancer Res 59: 3392-5, 1999. |
|
|
Nickerson T, Zhang J, Pollak M. Regression of DMBA-induced breast carcinoma following ovariectomy is associated with increased expression of genes encoding insulin-like growth factor binding proteins. Int J Oncol. 14: 987-90, 1999. |
|
|
Rosen C and Pollak M. Circulating IGF-I: a new perspective for a new century. Trends Endocrinol Metab. 10: 136-41, 1999. |
|
|
Pollak M. IGF-I physiology and breast cancer. Recent Results Cancer Rev. 17: 383-90, 1998-1999. |
|
|
Pollak M, Beamer W, Zhang J. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev. 17: 383-90, 1999. |
|
|
Ma J, Pollak M, Giovannucci E, Chan J, Tao Y, Hennekens C, Stampfer M. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein 3. J Natl Cancer Inst.91: 620-5, 1999 |
|
|
Ingle J, Suman V, Kardinal C, Krook J, Mailliard J, Veeder M, Loprinzi C, Dalton R, Hartmann L, Conover C, Pollak M. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85: 1284-92, 1999. |
|
|
Burrow S, Andrulis I, Pollak M, Bell R. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol. 69: 21-7, 1998. |
|
|
Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breastcancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol. 13: 865-9, 1998. |
|
|
Huynh H, Pollak M, Zhang J. Regulation of IGF-II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB 1089. Int J Oncol. 13: 137-143, 1998. |
|
|
Pollak M. Effects of anti-estrogens on insulin-like growth factor-I physiology systemically and in the uterus. Eur J Cancer. 34 (Supp 4) S1-S8, 1998. |
|
|
Hankinson S, Willett W, Colditz G, Hunter D, Michaud D, Deroo B, Rosner B, Speizer F, Pollak M. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet 351: 1393-96, 1998. [see also favorable editorial comment [.pdf] : Lancet 351: 1373-4, 1998] |
|
|
Pollak M. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res. Treat. 47: 209-17, 1998. |
|
|
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens C, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998 [see also favorable editorial comment [.pdf] - Science 279: 475, 1998] |
|
|
Pollak M, Schally A. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc for Exp Biol Med. 217: 143-52, 1998. |
|
|
Nickerson T, Pollak M,Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding IGF binding proteins 2,3,4, and 5. Endocrinology 139: 807-810, 1998. |
|
|
Pollak M. The potential role of somatostatin analogues in breast cancer treatment. Yale J Biol Med. 70:535-9, 1997. |
|
|
Huynh H, Beamer W, Pollak M. Overexpression of IGFBP-4 by MCF-7 breast cancer cells is associated with reduced responsiveness to IGFs in vitro and reduced tumor growth in vivo. Int J Oncol 11: 193-7, 1997. |
|
|
Foulkes W, Wong N, Brunet J, Begin L, Zhang J, Martinez J, Rozen F, Tonin P, Narod S, Karp S, Pollak M. Germ line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res. 3: 2465-9, 1997. |
|
|
Huynh H, Pollak M. Stabilization of mammary-derived growth inhibitor messenger RNA by antiestrogens. Clin Cancer Res. 3: 2151-6, 1997. |
|
|
Nickerson T, Huynh H, Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun. 237: 690-93, 1997. |
|
|
Karp S, Tonin P, Begin L, Martinez J, Zhang J, Pollak M, Foulkes W. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80: 435-41, 1997. |
|
|
Rozen F, Yang X, Huynh H, Pollak M. Antiproliferative action of vitamin-D-related compounds and insulin-like growth factor binding protein 5 accumulation. J Natl Cancer Inst. 89: 652-6, 1997. |
|
|
Huynh H, Nickerson T, Pollak M, Yang X. Regulation of IGF-I receptor expression by the pure antiestrogen ICI 182780. Clin Cancer Res. 2: 2037-42, 1996. |
|
|
Huynh H, Yang YX, Pollak M. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Diff. 7: 1501-6, 1996. |
|
|
Huynh H, Alpert L, Pollak M. Pregnancy - dependent growth of mammary tumors is associated with overexpression of insulin-like growth factor II. Cancer Res. 56: 3651-4, 1996. |
|
|
Pollak M. Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. Digestion 57: 29-33, 1996. |
|
|
Pollak M. Peptide growth factors and breast cancer treatment: recent translational research. Recent Results Cancer Res.40: 43-9, 1996. |
|
|
Huynh H , Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem. 271: 1016-21, 1996. |
|
|
Huynh H, Alpert L, Pollak M. Silencing of the mammary derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. Cancer Res. 56: 4865-70, 1996. |
|
|
Phelan C, Larsson C, Baird S, Futreal A, Ruttledge M, Morgan K, Tonin P, Huynh H, Korneluk R, Pollak M, Narod S. The human mammary-derived growth inhibitor (MDGI) gene: genomic structure and mutation analysis in human breast tumors. Genomics 34: 63-68, 1996. [Dr. Pollak and Dr. Narod are co-senior authors who contributed equally to this work] |
|
|
Yang XF, Beamer WG, Huynh H, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the 'lit' mutation. Cancer Res 56: 1509-11, 1996. |
|
|
Huynh H, Pollak M. Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: correlations with effects on proliferation. Prog Growth Factor Res. 6: 495-501, 1995. |
|
|
Montaner J, Harris A, Amar J, Fanning M, and multicenter study group, (including Pollak M.). Octreotide therapy in AIDS-related refractory diarrhea: results of a multicenter Canadian-European study. AIDS 9: 209-10, 1995. |
|
|
Huynh H, Larsson C, Narod S, Pollak M. Tumor suppressor activity of the gene encoding mammary-derived growth inhibitor. Cancer Res. 55: 2225-31, 1995. |
|
|
Bloom C, Lisbona A, Bégin LR, Pollak M. Extraosseous Ewing's Sarcoma. Can Assoc Radiol J 46: 131-3, 1995. |
download |
|
Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, Andrulis IL. Insulin-like growth factor I (IGF-I) receptors, IGF-I, and IGF-II are expressed in primary human sarcomas. Cancer Res. 55: 129-34, 1995. |
|
|
Rosenberg L, Barkun A, Denis M, Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 75: 23-8, 1995. |
|
|
Huynh H, Pollak M. HH2A, an immortalized bovine breast epithelial cell line that expresses the gene encoding mammary-derived growth inhibitor. In Vitro Cell Dev Biol Anim. 31: 25-9, 1995. |
|
|
Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-Dimethylbenz (alpha) anthracene-induced rat mammary carcinomas. Cancer Res 54: 6334-7, 1994. [A footnote identifies Dr. Pollak and Dr. Bruns as co-senior authors who contributed equally to this work.] |
|
|
Huynh H, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun. 203: 253-9, 1994. |
|
|
Huynh H, Pollak M. Uterotrophic actions of estradiol and tamoxifen are associated with inhibition of uterine insulin-like growth factor binding protein 3 gene expression. Cancer Res. 54: 3115-9, 1994. |
|
|
Sekyi-Otu A, Bell R, Andrulis I, Pollak M. Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement. J Natl Cancer Inst. 86: 628-32, 1994. |
|
|
Pratt S, Pollak M. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem Biophys Res Commun. 198: 292-7, 1994. |
|
|
Huynh H, Pollak M. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53: 5585-8, 1993. |
|
|
Tonin P, Ehrenborg W, Lenoir G, Feunteun J, Lynch H, Morgan K, Zazzi H, Vivier A, Pollak M, Huynh H, et al. The human insulin-like growth factor- binding protein 4 gene maps to chromosome region 17q12-21.1 and is close to the gene for hereditary breast-ovarian cancer. Genomics 18: 414-7, 1993. |
|
|
Pollack R, Pollak M, Rochon L. Pregnancy complicated by medulloblastoma with metastases to the placenta. Obstet Gynecol 81: 858-9, 1993. |
|
|
Pratt S, and Pollak MN. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 53: 5193-8, 1993. |
|
|
Huynh H, Tetenes E, Wallace L, Pollak M. In vivo inhibition of insulin-like growth factor 1 gene expression by tamoxifen. Cancer Res 53: 1727-30, 1993. |
|
|
Friedel A, Jordan V, Pollak M. Suppression of serum insulin-like growth factor-I levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 29a: 1368-72, 1993. |
|
|
Pollak M, Galant K, Poisson R, Harris A. Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial. Metabolism: 41: 9 Suppl 2, 119-120, 1992. |
|
|
Pollak MN, Huynh H, Lefebvre S. Tamoxifen reduces serum-like growth factor I (IGF-I). Breast Cancer Res Treat. 22: 91-100, 1992. |
|
|
Pollak M, Sem A, Richard M, Tetenes E, Bell R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 84: 966-71, 1992. |
|
|
Tannenbaum G, Gurd W, Lapointe M, Pollak M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 130: 3395-401, 1992. |
|
|
Malaab S, Pollak MN, Goodyer CG. Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur J Cancer 28A: 788-93, 1992. |
|
|
Yao XJ, Wainberg MA, Pollak M. The inhibitory effects of suramin on HIV-1 are attenuated in the presence of albumin. AIDS 5: 1389-91, 1991. |
|
|
Yao XJ, Wainberg MA, Richard M, Pollak M. The ability of suramin to block CD4-gp120 binding is reduced in the presence of albumin. Antimicrobial agents and chemotherapy 35: 2636-8, 1991. |
|
|
Pollak M, Gora P, Boyarsky A. A mathematical model describing consequences of abnormally high levels of epidermal growth factor receptor on the proliferation of neoplastic cells. Cancer Invest. 9: 513-20, 1991. |
|
|
Dawson N, Costanza M, Korzun A, Clamon G, Pollak M, Vogelzong N, Carey R, Norton L. Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. Med and Pediatr Oncol 19: 283-288, 1991. |
|
|
Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst. 82: 1693-7, 1990. [see also favorable editorial comment: J Natl Cancer Inst. 82: 1662-1663, 1990] |
|
|
Panasci L, Shenouda G, Begin L, Pollak M, Reinke A, Margolese R. Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. Cancer Chemother Pharmacol 26: 457-60, 1990. |
|
|
Pollak M, Polychronakos C, Richard M. Insulin-like growth factor 1: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst. 82: 301-5, 1990. |
|
|
Pollak M, Richard M. Suramin blockade of insulin-like growth factor I- stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 82: 1349-52, 1990. |
|
|
Suissa S, Pollak M, Spitzer W, Margolese R. Body size and breast cancer prognosis: a statistical explanation of the discrepancies. Cancer Research 49: 3113-6, 1989. |
|
|
Pollak M, Polychronakos C, Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-1 levels in patients with neoplasms potentially dependent on IGF-1. Anticancer Research 9: 889-891, 1989. |
|
|
Pollak M, Polychronakos C, Yousefi S, Richard M. Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem. Biophys. Res. Commun. 154: 326-31, 1988. |
|
|
Gonzalez-Vela JL, Panasci L, Black M, Pollak M, Margolese R. Combination chemotherapy with carboplatinum and bleomycin for advanced and recurrent head and neck cancer. A phase II study. J. Surgical Oncology 39: 215-6, 1988. |
|
|
Filmus J, Trent JM, Pollak MN, Buick RN. Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants. Mol and Cell Biol. 7: 251-257, 1987. |
|
|
Pollak M, Perdue J, Margolese R, Baer K, Richard M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Letters 38: 223-230, 1987. |
|
|
Filmus J, Pollak MN, Cailleau R, Buick RN. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem. Biophys. Res. Commun. 128: 898-905, 1985. |
|
|
Filmus J, Pollak MN, Cairncross J, Buick RN. Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. Biochem. Biophys. Res. Commun. 131: 207-215, 1985. |
|
|
Buick RN, and Pollak MN. Perspectives on clonogenic tumor cells, stem cells, and oncogenes. Cancer Research 44: 4909-18, 1984. |
|
|
Pollak M. Computer-aided information management systems in clinical trials: a physician's perspective. Computer Prog. Biomed. 16: 243-52, 1983. |
|
|
Fletcher S, Ratzer G, Pollak M. Computer-based appointment scheduling for ambulatory patients. Meth. Information Med. 17: 167-72, 1978. |